We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+50.7%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.36B
AUM Growth
+$330M
(+32%)
Cap. Flow
-$51.5M
Cap. Flow
% of AUM
-3.79%
Top 10 Holdings %
Top 10 Hldgs %
77.83%
Holding
43
New
3
Increased
11
Reduced
10
Closed
9
Top Buys
| 1 |
Nurix Therapeutics
NRIX
|
+$63.4M |
| 2 |
Scholar Rock
SRRK
|
+$49.4M |
| 3 |
Annexon
ANNX
|
+$14.3M |
| 4 |
Immunome
IMNM
|
+$12.2M |
| 5 |
RAPT
RAPT Therapeutics
RAPT
|
+$10.4M |
Top Sells
| 1 |
Zymeworks
ZYME
|
+$70.1M |
| 2 |
LivaNova
LIVN
|
+$46.2M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$35.5M |
| 4 |
Cogent Biosciences
COGT
|
+$21.7M |
| 5 |
ETNB
89bio
ETNB
|
+$21.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Celldex Therapeutics
CLDX
$2.74B
| $7.69M | 0.57% |
283,308
-43,700
| -13% | -$1.15M |
|
|
27
LivaNova
LIVN
$4.44B
| $7.26M | 0.53% |
118,054
-808,745
| -87% | -$46.2M |
|
28
Invivyd
IVVD
$228M
| $6.62M | 0.49% |
2,681,159
+395,839
| +17% | +$823K |
|
29
Xenon Pharmaceuticals
XENE
$6.66B
| $6M | 0.44% |
+133,882
| New | +$5.62M |
|
|
RPTX
30
DELISTED
Repare Therapeutics
RPTX
| $4.12M | 0.3% |
1,586,174
| – | – |
|
31
ALX Oncology
ALXO
$285M
| $3.69M | 0.27% |
3,264,718
-68,265
| -2% | -$103K |
|
32
Oric Pharmaceuticals
ORIC
$1.1B
| $3.67M | 0.27% |
+448,110
| New | +$5.16M |
|
33
Pliant Therapeutics
PLRX
$68.1M
| $1.97M | 0.15% |
1,616,228
+24,533
| +2% | +$36.9K |
|
|
KLRS
34
Kalaris Therapeutics
KLRS
$128M
| $700K | 0.05% |
82,955
| – | – |
|
|
AKRO
35
DELISTED
Akero Therapeutics
AKRO
| – | – |
-747,818
| Closed | -$35.5M |
|
|
ETNB
36
DELISTED
89bio
ETNB
| – | – |
-1,473,136
| Closed | -$21.7M |
|
|
FOLD
37
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-777,178
| Closed | -$6.12M |
|
38
Keros Therapeutics
KROS
$212M
| – | – |
-552,506
| Closed | -$8.74M |
|
|
LVTX
39
DELISTED
LAVA Therapeutics
LVTX
| – | – |
-2,074,372
| Closed | -$3.24M |
|
40
Prime Medicine
PRME
$573M
| – | – |
-87,118
| Closed | -$483K |
|
|
VTYX
41
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-1,073,386
| Closed | -$3.34M |
|
42
Xeris Biopharma Holdings
XERS
$1.53B
| – | – |
-451,099
| Closed | -$3.67M |
|
|
BOLD
43
Boundless Bio
BOLD
$55.3M
| – | – |
-245,458
| Closed | -$302K |
|
Similar funds
ORI
KP
FMI
FCM
SCM
PP
AM
BFO
Redmile Group's Q4 2025 Portfolio in Review
As of Q4 2025, Redmile Group held 43 positions worth $1.36B, up 32% from $1.03B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Redmile Group withdrew a net $51.5M in Q4 2025, closing 9 positions and reducing 10 holdings. Its most notable exit was Akero Therapeutics, an estimated $35.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Redmile Group opened a new position in DBV Technologies worth $10.5M.
- Redmile Group's largest Q4 2025 buy was DBV Technologies: 549,840 shares worth $10.5M.
- Redmile Group added most to Nurix Therapeutics in Q4 2025, an estimated $63.4M increase.
- Redmile Group's biggest Q4 2025 reduction was Zymeworks, cutting an estimated $70.1M.
- Redmile Group fully exited Akero Therapeutics in Q4 2025, selling an estimated $35.5M.
- Redmile Group's ten largest holdings make up 78% of its $1.36B portfolio in Q4 2025.
- Redmile Group opened 3 new positions and closed 9 in Q4 2025.
- Redmile Group's portfolio value rose 32% quarter-over-quarter to $1.36B.
Based on Redmile Group's 13F filing for Q4 2025, filed 17 Feb 2026.